摘要目的 探讨microRNA-223( miR-223)表达与弥漫性大B细胞淋巴瘤(DLBCL)免疫亚型及预后的相关关系.方法 应用免疫组织化学EnVision法对山西省肿瘤医院病理科有详细随访资料的45例DLBCL进行CD20、CD3、CD10、bcl-6、MUM-1免疫标记,根据Hans分类方法将DLBCL分为生发中心B细胞型(GCB型)和非GCB型;应用安捷伦16.0高密度芯片对24例有详细随访资料的DLBCL患者的石蜡样本进行miRNA表达谱筛选;采用TaqMan real-time逆转录聚合酶链反应( real-time RT-PCR)检测miR-223的表达水平,14例淋巴结反应性增生样本作为对照.结果 45例DLBCL中,GCB型16例(35.6％),非GCB型29例(64.4％).miR-223在GCB型中的相对表达量为19.8,在非GCB型中的相对表达量为15.8,二者差异无统计学意义(P=0.236).与淋巴结反应性增生相比较,miR-223在DLBCL中表达上调,其表达量是淋巴结反性增生的17.2倍,差异有统计学意义(P=0.014).DLBCL中miR-223高表达组(＞中位数)总体生存率高于低表达组(＜中位数),差异有统计学意义(P=0.011).多因素Cox模型分析显示:45例DLBCL中,miR-223低表达组(RR =5.445,95％CI 1.555～ 19.068,P=0.008)、乳酸脱氢酶异常水平(RR =3.974,95％ CI1.191～13.266,P =0.025)、国际预后指数≥3分(RR =4.044,95％CI 1.233～13.264,P=0.021)均为各自独立的预后不良的因素.结论 DLBCL中miR-223的表达与免疫亚型无关,miR-223高表达组总体生存率明显高于低表达组,提示miR-223可能为评估预后的另一个新型分子标志物.

abstractsObjective To study the expression of miR-223 in diffuse large B cell lymphoma (DLBCL) with correlation of histoloigcal subtypes and clinical prognosis.Methods A total of 45 cases of DLBCL were investigated by immunohistochemistry ( EnVision method) for CD20,CD3,CD10,bcl-6 and MUM-1.The cases were classified into germinal center B cell-like (GCB) and non-germinal center B celllike (non-GCB) subtypes according to Hans'algorithm.Agilent Human miRNA MicrOarray 16.0 was used to detect the expression of micro-RNAs in paraffin-embedded tissue of 24 cases of DLBCL that had available clinical follow-up.The expression levels of miR-223 were examined by TaqMan real-time reverse transcription polymerase chain reaction ( real-time RT-PCR).Fourteen cases of reactive lymph node were selected as control.Results Among 45 cases of DLBCL,16 cases ( 35.6％ ) were GCB,and 29 cases(64.4％ ) were non-GCB subtypes.The expression levels of miR-223 measured by real-time RT-PCR were 19.8 and 15.8 in GCB and non-GCB subgroups,respectively (P =0.236).The expression of miR-223 was up-regulated in DLBCL with 17.2 folds of increase over that of the reactive lymph nodes ( P =0.014).The overexpression of miR-223 was significandy correlated with a longer overall survival ( P =0.011 ).Multivariate Cox proportional hazard regression analysis identified the following independent poor prognostic factors:low expression of miR-223 (RR =5.445,95％ CI,1.555-19.068,P =0.008 ),abnormal level of LDH (RR=3.974,95％ CI,1.191-13.266,P=0.025) and IPI≥3 (RR =4,044,95％ CI,1.233-13.264,P =0.021).Conclusious The expression of miR-223 has no relationship with the immunophenotypes of DLBCL.As a potential prognostic biomarker,overexpression of miR-223 correlates with a longer OS of patients with DI,BCL.